The global T-cell therapy market size is expected to reach USD 30.83 billion by 2030 and is expected to register a CAGR of 17.6% from 2023 to 2030. The landmark approval of Kymriah and Yescarta have boosted advancements in the market. The launch of such therapies has strenghtned cash flow for innovation in this area resulting in market growth.
The shifting patients’ preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.
Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.
An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.
The development of CAR T treatments for non-hematological malignancies has been significantly hampered by the antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilising a data-driven approach to research this area.
The shifting patients’ preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.
Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.
An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.
The development of CAR T treatments for non-hematological malignancies has been significantly hampered by the antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilising a data-driven approach to research this area.
T-cell Theraphy Market Report Highlights
- By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.
- Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.
- By therapy type, CAR-T cell therapy dominated the segment in 2022 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.
- Haematological malignancies dominated the indication segment in 2022. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.
- North America dominated the overall global market. The regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.
Table of Contents
Chapter 1 Research Methodology1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Competition Milieu
2.2 Market Snapshot
2.3 Segment Outlook
Chapter 3 Market Variables, Trends, & Scope
3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
3.2 T-Cell Therapy - Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
3.2.1.2 Growing competition among market players
3.2.1.3 Approval of Kymriah and Yescarta across various countries
3.2.1.4 Developments in CAR T-cell therapy for solid tumors
3.2.1.5 Technological advancements in manufacturing process
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.2.2.1 High prices of therapies
3.2.2.2 CAR T limitations
3.2.3 Opportunity analysis
3.2.3.1 Facility expansion for cell and gene therapies
3.2.3.1 Rising global financings in gene and cell therapy arena
3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
3.3 Regulatory Landscape
3.3.1 Current and potential future approvals
3.3.2 Frameworks for risk mitigation and safety monitoring
3.3.3 Regulatory framework, by geography
3.3.3.1 U.S.
3.3.3.2 Europe
3.3.3.3 China
3.3.3.4 Japan
3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
3.4.1 Insurance coverage
3.4.2 Value-based price benchmarks
3.4.3 Alternate payment strategies
3.5 Patent Landscape
3.6 Deals, Funding's, Partnerships and Collaborations
3.6.1 Licensing deals
3.6.2 Merger & acquisition deals
3.6.3 Collaboration & partnerships
3.7 Pipeline Analysis
3.7.1 Clinical trial landscape
3.8 Geographic Mapping of Companies
3.9 Competitive Landscape for CD19directed CART Therapies and Other T-cell therapies
3.10 T-cell Therapy Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10.1 Political landscape
3.10.2 Economic landscape
3.10.3 Social landscape
3.10.4 Technology landscape
3.11 Industry Analysis - Porter’s
3.11.1 Supplier bargaining power
3.11.2 Buyer bargaining power
3.11.3 Substitution threat
3.11.4 Threat from new entrant
3.11.5 Competitive rivalry
Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis
4.1 T-cell Therapy Market: Modality Movement Analysis
4.2 Research
4.2.1 Global research-based T-cell therapy market, 2018 - 2030 (USD Million)
4.3 Commercialized
4.3.1 Global commercial T-cell therapy market, 2018 - 2030 (USD Million)
Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
5.1 T-cell Therapy Market: Therapy Type Movement Analysis
5.2 CAR T-cell Therapy
5.2.1 Global CAR T-cell Therapy market, 2018 - 2030 (USD Million)
5.3 T Cell Receptor (TCR)-based
5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2018 - 2030 (USD Million)
5.4 Tumor Infiltrating Lymphocytes (TIL)-based
5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2018 - 2030 (USD Million)
Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis
6.1 T-cell Therapy Market: Indication Movement Analysis
6.2 Hematologic Malignancies
6.2.1 Global T-cell therapy market for hematologic malignancies, 2018 - 2030 (USD Million)
6.2.2 Lymphoma
6.2.2.1 Global T-cell therapy market for lymphoma, 2018 - 2030 (USD Million)
6.2.3 Leukemia
6.2.3.1 Global T-cell therapy market for leukemia, 2018 - 2030 (USD Million)
6.2.4 Myeloma
6.2.4.1 Global T-cell therapy market for myeloma, 2018 - 2030 (USD Million)
6.3 Solid Tumors
6.3.1 Global T-cell therapy market for solid tumors, 2018 - 2030 (USD Million)
6.3.2 Melanoma
6.3.2.1 Global T-cell therapy market for melanoma, 2018 - 2030 (USD Million)
6.3.3 Brain & Central Nervous System
6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2018 - 2030 (USD Million)
6.3.4 Liver cancer
6.3.4.1 Global T-cell therapy market for liver cancer, 2018 - 2030 (USD Million)
6.3.5 Others
6.3.5.1 Global T-cell therapy market for other cancer forms, 2018 - 2030 (USD Million)
6.4 Others
6.4.1 Global T-cell therapy market for others, 2018 - 2030 (USD Million)
Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality, Therapy Type & Indication
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key country dynamics
7.1.2.2 Target disease prevalence
7.1.2.3 Competitive scenario
7.1.2.4 Regulatory framework
7.1.2.5 Reimbursement scenario
7.1.2.6 U.S. T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key country dynamics
7.1.3.2 Target disease prevalence
7.1.3.3 Competitive scenario
7.1.3.4 Regulatory framework
7.1.3.5 Reimbursement scenario
7.1.3.6 Canada T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis
7.2.1.1 Europe T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key country dynamics
7.2.2.2 Target disease prevalence
7.2.2.3 Competitive scenario
7.2.2.4 Regulatory framework
7.2.2.5 Reimbursement scenario
7.2.2.6 Germany T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.3 UK
7.2.3.1 Key country dynamics
7.2.3.2 Target disease prevalence
7.2.3.3 Competitive scenario
7.2.3.4 Regulatory framework
7.2.3.5 Reimbursement scenario
7.2.3.6 UK T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key country dynamics
7.2.4.2 Target disease prevalence
7.2.4.3 Competitive scenario
7.2.4.4 Regulatory framework
7.2.4.5 Reimbursement scenario
7.2.4.6 France T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key country dynamics
7.2.5.2 Target disease prevalence
7.2.5.3 Competitive scenario
7.2.5.4 Regulatory framework
7.2.5.5 Reimbursement scenario
7.2.5.6 Italy T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key country dynamics
7.2.6.2 Target disease prevalence
7.2.6.3 Competitive scenario
7.2.6.4 Regulatory framework
7.2.6.5 Reimbursement scenario
7.2.6.6 Spain T-cell therapy market estimates and f.orecasts, 2018 - 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key country dynamics
7.2.7.2 Target disease prevalence
7.2.7.3 Competitive scenario
7.2.7.4 Regulatory framework
7.2.7.5 Reimbursement scenario
7.2.7.6 Denmark T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key country dynamics
7.2.8.2 Target disease prevalence
7.2.8.3 Competitive scenario
7.2.8.4 Regulatory framework
7.2.8.5 Reimbursement scenario
7.2.8.6 Sweden T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key country dynamics
7.2.9.2 Target disease prevalence
7.2.9.3 Competitive scenario
7.2.9.4 Regulatory framework
7.2.9.5 Reimbursement scenario
7.2.9.6 Norway T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2.10 Rest Of Europe T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT analysis
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Target disease prevalence
7.3.2.2 Competitive scenario
7.3.2.3 Regulatory framework
7.3.2.4 Reimbursement scenario
7.3.2.5 Japan T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Target disease prevalence
7.3.3.2 Competitive scenario
7.3.3.3 Regulatory framework
7.3.3.4 Reimbursement scenario
7.3.3.5 China T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Target disease prevalence
7.3.4.2 Competitive scenario
7.3.4.3 Regulatory framework
7.3.4.4 Reimbursement scenario
7.3.4.5 India T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.5 South Korea
7.3.5.1 Target disease prevalence
7.3.5.2 Competitive scenario
7.3.5.3 Regulatory framework
7.3.5.4 Reimbursement scenario
7.3.5.5 South Korea T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.6 Australia
7.3.6.1 Target disease prevalence
7.3.6.2 Competitive scenario
7.3.6.3 Regulatory framework
7.3.6.4 Reimbursement scenario
7.3.6.5 Austrlia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.7 Thailand
7.3.7.1 Target disease prevalence
7.3.7.2 Competitive scenario
7.3.7.3 Regulatory framework
7.3.7.4 Reimbursement scenario
7.3.7.5 Thailand T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.8 Rest Of Asia Pacific T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Latin America
7.4.1 SWOT Analysis
7.4.2 Key Regional Dynamics
7.4.2.1 Latin America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.3 Brazil
7.4.3.1 Target disease prevalence
7.4.3.2 Competitive scenario
7.4.3.3 Regulatory framework
7.4.3.4 Reimbursement scenario
7.4.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.4 Mexico
7.4.4.1 Target disease prevalence
7.4.4.2 Competitive scenario
7.4.4.3 Regulatory framework
7.4.4.4 Reimbursement scenario
7.4.4.5 Mexico T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.5 Argentina
7.4.5.1 Target disease prevalence
7.4.5.2 Competitive scenario
7.4.5.3 Regulatory framework
7.4.5.4 Reimbursement scenario
7.4.5.5 Argentina T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.6 Rest Of Latam T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis
7.5.2 KEY regional Dynamics
7.5.2.1 Middle East & Africa T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.3 South Africa
7.5.3.1 Target disease prevalence
7.5.3.2 Competitive scenario
7.5.3.3 Regulatory framework
7.5.3.4 Reimbursement scenario
7.5.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.4 Saudi Arabia
7.5.4.1 Target disease prevalence
7.5.4.2 Competitive scenario
7.5.4.3 Regulatory framework
7.5.4.4 Reimbursement scenario
7.5.4.5 Saudi Arabia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.5 UAE
7.5.5.1 Target disease prevalence
7.5.5.2 Competitive scenario
7.5.5.3 Regulatory framework
7.5.5.4 Reimbursement scenario
7.5.5.5 UAE T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.6 Kuwait
7.5.6.1 Target disease prevalence
7.5.6.2 Competitive scenario
7.5.6.3 Regulatory framework
7.5.6.4 Reimbursement scenario
7.5.6.5 Kuwait T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.7 Rest of MEA T-cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Company Profiles
8.2.1 Novartis AG
8.2.1.1 Company overview
8.2.1.1.1 AveXis, Inc.
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 Gilead Sciences
8.2.2.1 Company overview
8.2.1.1.1 Kite Pharma
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives
8.2.3 bluebird bio, Inc.
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.3.4 Strategic initiatives
8.2.4 TCR2 Therapeutics Inc
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Sorrento Therapeutics
8.2.5.1 Company overview
8.2.5.2 Product benchmarking
8.2.5.3 Strategic initiatives
8.2.6 Fate Therapeutics
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Product benchmarking
8.2.6.3 Strategic initiatives
8.2.7 Merck KGaA
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.3 Strategic initiatives
8.2.8 Pfizer Inc.
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 Amgen
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives
8.2.10 Celgene Corporation
8.2.10.1 Company overview
8.2.10.1.1 Juno Therapeutics
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 4 Global T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 5 Global T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 6 Global T-Cell Therapy Market by Region, 2018 - 2030 (USD Million)
Table 7 North America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 8 North America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 9 North America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 10 North America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 11 U.S. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 12 U.S. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 13 U.S. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 14 Canada T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 15 Canada T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 16 Canada T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 17 Europe T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 18 Europe T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 19 Europe T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 20 Europe T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 21 Germany T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 22 Germany T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 23 Germany T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 24 U.K. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 25 U.K. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 26 U.K. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 27 France T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 28 France T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 29 France T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 30 Italy T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 31 Italy T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 32 Italy T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 33 Spain T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 34 Spain T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 35 Spain T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 36 Denmark T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 37 Denmark T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 38 Denmark T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 39 Sweden T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 40 Sweden T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 41 Sweden T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 42 Norway T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 43 Norway T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 44 Norway T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 45 Asia Pacific T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 47 Asia Pacific T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 48 Asia Pacific T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 49 China T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 50 China T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 51 China T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 52 Japan T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 53 Japan T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 54 Japan T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 55 India T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 56 India T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 57 India T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 58 South Korea T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 59 South Korea T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 60 South Korea T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 61 Australia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 62 Australia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 63 Australia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 64 Thailand T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 65 Thailand T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 66 Thailand T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 67 Latin America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 68 Latin America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 69 Latin America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 70 Latin America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 71 Brazil T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 72 Brazil T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 73 Brazil T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 74 Mexico T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 75 Mexico T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 76 Mexico T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 77 Argentina T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 78 Argentina T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 79 Argentina T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 84 South Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 85 South Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 86 South Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 90 UAE T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 91 UAE T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 92 UAE T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 93 Kuwait T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 94 Kuwait T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 95 Kuwait T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 T-Cell Therapy, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
Fig. 14 Regional Marketplace: Key Takeaways
Fig. 15 Global T-Cell Therapy Market for Commercialized,2018 - 2030 (USD Million)
Fig. 16 Global T-Cell Therapy Market for Research, 2018 - 2030 (USD Million)
Fig. 17 Global T-Cell Therapy Market for In-Situ Hybridization Diagnostics, 2018 - 2030 (USD Million)
Fig. 18 Global T-Cell Therapy Market for CAR T Cell Therapy, 2018 - 2030 (USD Million)
Fig. 19 Global T-Cell Therapy Market for T Cell Receptor (TCR)-based,2018 - 2030 (USD Million)
Fig. 20 Global T-Cell Therapy Market for Tumor Infiltrating Lymphocytes (TIL)-based, 2018 - 2030 (USD Million)
Fig. 21 Global T-Cell Therapy Market for Hematologic Malignancies,2018 - 2030 (USD Million)
Fig. 22 Global T-Cell Therapy Market for Lymphoma, 2018 - 2030 (USD Million)
Fig. 23 Global T-Cell Therapy Market for Leukemia, 2018 - 2030 (USD Million)
Fig. 24 Global T-Cell Therapy Market for Myeloma, 2018 - 2030 (USD Million)
Fig. 25 Global T-Cell Therapy Market for Solid Tumors, 2018 - 2030 (USD Million)
Fig. 26 Global T-Cell Therapy Market for Melanoma, 2018 - 2030 (USD Million)
Fig. 27 Global T-Cell Therapy Market for Brain and central nervous system, 2018 - 2030 (USD Million)
Fig. 28 Global T-Cell Therapy Market for Liver cancer,2018 - 2030 (USD Million)
Fig. 29 Global T-Cell Therapy Market for Others,2018 - 2030 (USD Million)
Fig. 30 Global T-Cell Therapy Market for Other Indications, 2018 - 2030 (USD Million)
Fig. 31 Regional Outlook, 2021 & 2030
Fig. 32 North America T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 33 U.S. T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 34 Canada T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 35 Europe T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 36 Germany T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 37 U.K. T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 38 France T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 39 Italy T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 40 Spain T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 41 Denmark T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 42 Sweden T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 43 Norway T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 45 Japan T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 46 China T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 47 India T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 48 Australia T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 49 South Korea T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 50 Thailand T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 51 Latin America T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 52 Brazil T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 53 Mexico T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 54 Argentina T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 56 South Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 58 UAE T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 59 Kuwait T-Cell Therapy Market 2018 - 2030 (USD Million)
Companies Mentioned
- Novartis AG
- Gilead Sciences
- bluebird bio, Inc.
- TCR2 Therapeutics Inc
- Sorrento Therapeutics
- Fate Therapeutics
- Merck KGaA
- Pfizer Inc.
- Amgen
- Celgene Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 8344.7 Million |
| Forecasted Market Value ( USD | $ 30830 Million |
| Compound Annual Growth Rate | 17.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
